Status: Recruiting
Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients
The primary purpose of this study is to evaluate whether the drug EI-001 can help improve vitiligo symptoms. EI-001 is a novel antibody drug that affects the immune system to decrease uncontrolled inflammation. EI-001 has been investigated in human cell cultures, animal studies, and in a Phase 1 healthy volunteer study. The results so far show that EI-001 is a tolerable and potential new treatment for immune diseases such as vitiligo.
Participants needed: 45
Trial details
Phase: Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: Elixiron Immunotherapeutics (Hong Kong) Ltd.Updated: Jun 5, 2026Locations: 6
Eligibility criteria
Able to understand and voluntarily sign the informed consent form (ICF). [+8]
Non-eligible skin conditions: Other types of vitiligo (e.g., segmental) or other... [+13]